Time filter

Source Type

Klek S.,Oddzial Chirurgii Ogolnej i Onkologicznej | Jankowski M.,Nicolaus Copernicus University | Kruszewski W.J.,Medical University of Gdansk | Fijuth J.,Medical University of Lodz | And 5 more authors.
Nowotwory | Year: 2015

Malnutrition affects a large part of patients with malignant neoplasm. Proper nutritional treatment determines the effectiveness and success of therapy in these patients. Given the importance of this issue, thanks to the collaboration of scientific societies: Polish Society of Surgical Oncology (PTChO), Polish Society of Oncology (PTO), Polish Society of Clinical Oncology (PTOK) and Polish Society for Parenteral, Enteral Nutrition and Metabolism (POLSPEN) standards for nutritional therapy in oncology have been set. An introduction to nutritional therapy is the correct identification of malnourished patients. In Poland, hospitalized patients are subject to screening towards malnutrition. Nutrition intervention should be tailored to the clinical situation. It involves the use of dietary advice, use of oral diet products (oral nutritional support), enteral or parenteral nutrition, in hospital or in home, in consideration of special situations. © Polskie Towarzystwo Onkologiczne.

Jassem J.,Medical University of Gdansk | Duchnowska R.,Klinika Onkologii | Kawecki A.,Klinika Nowotworow Glowy I Szyi | Krajewski R.,Klinika Nowotworow Glowy I Szyi | And 7 more authors.
Nowotwory | Year: 2014

Surveillance after oncological treatment constitutes a necessary element of comprehensive cancer care. Determining optimal follow-up schedules, including their cost effectiveness, is critical on clinical, organisational and economic grounds. Owing to a lack of prospective clinical studies providing the highest level of evidence, in most cancers optimal surveillance schemes cannot be determined. Hence, currently most recommendations are based on retrospective studies and expert opinions. In Poland comprehensive and uniform recommendations on post-treatment surveillance in cancer patients are not available. This article, prepared by a group of experts in oncology and family medicine, presents a proposal for the follow-up schemes after treatment in major solid malignancies in adults. © Polskie Towarzystwo Onkologiczne.

Hazards related with the choice of progression-free survival as a criterion for assessment of the value of systemic anticancer therapy are presented in this study. The arguments for overall survival as reliable end-point in clinical trials in oncology are discussed. © Polskie Towarzystwo Onkologiczne.

Clinical trials are fundamental for the advancement of knowledge in medical sciences (including oncology) therefore strict legal and ethical conditions should be applied to their planning and conducting. Regulation No 536/2014 of the European Parliament was enforced in June 2014 to increase the number of clinical trials conducted in EU Member States. This new legislation regulates clinical trials and is mandatory in all EU countries. These new rules not only simplify the application procedure for authorization of a clinical trial and shorten waiting time for the authorization to begin study, but also introduce new definitions, including biomedical trials or clinical trials with a low degree of intervention. Particularly significant changes concern non-commercial research, including academic research projects in medicine and trials initiated by investigators (Investigator Initiated Study) based on universities, scientific societies, scientific research groups or research institutes. According to the provisions of the Regulation, it is necessary to take national legislative measures in order to support such projects. Therefore, oncology societes in our country propose means to enhance non-commercial clinical trials to be conducted in Poland.

Salamacha M.,Klinika Nowotworow Tkanek Miekkich | Kosela H.,Klinika Nowotworow Tkanek Miekkich | Falkowski S.,Klinika Nowotworow Tkanek Miekkich | Cybulska-Stopa B.,Klinika Nowotworow Ukladowych I Uogolnionych | And 2 more authors.
Nowotwory | Year: 2011

Neurofibromatosis comprises a group of three disorders - schwannomatosis, type 2 neurofibromatosis, and the most common - type 1 neurofibromatosis (NF1). NF1 is inherited in an autosomal dominant fashion and is found in 1 per 3500 live births. Type 1 neurofibromatosis is caused by a mutation in the NF1 gene, the gene product being neurofibromin . This protein is a negative regulator of the Ras kinase pathway. Neurofibromin alters or weakens this protein, allowing rapid, uncontrolled growth of cells. The range of symptoms is very wide; they vary from minor cutaneus lesions to malignancies. NF1 is associated with a higher incidence of soft tissue sarcomas, such as MPNST and GIST. MPNST arise from preexisting plexiform neurofibromas, due to a somatic mutation leading to the loss of heterozygosity of the NF1 gene. It requires intensive treatment modalities, often leading to disability and the prognosis is often poor. New therapeutic modalities have been investigated recently, as a consequence of discovering cell pathways leading to this type of cancer. GIST (gastrointestinal stromal tumor) is another soft tissue sarcoma often occurring in NF1 patients. Imatinib - an inhibitor of tyrosine kinases - applied as a standard therapy in the group of sporadic GIST, can be useless for NF1 patients with GIST, because of different pathogenesis.

Discover hidden collaborations